RxDoctor Payments Data

Andrea Semones, APRN

Psychiatric/Mental Health · Frankfort, KYNPI 1932539053

Payments from drug & device makers

$3,033in general payments, 2019–2025

Across 175 payments — averaging $17.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$791
  • Otsuka America Pharmaceutical, Inc.$483
  • Johnson & Johnson$455
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$271
  • Vanda Pharmaceuticals Inc.$229
  • Axsome Therapeutics, Inc.$199
  • plus $604 from 12 others

What the payments were for

  • Food & beverage$3,033100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,033 in reported general payments places this provider in the 80th percentile of 946 psychiatric/mental health providers in Kentucky.

See all psychiatric/mental health providers in Kentucky

Medicare billing

Part B allowed, 2024
$5,134
Medicare patients
19
Services billed
64

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole23$33,561
VraylarCariprazine Hcl21$33,275
TrintellixVortioxetine Hydrobromide15$8,143
Atomoxetine Hcl20$2,703
Desvenlafaxine Succinate ErDesvenlafaxine Succinate36$2,034
Aripiprazole30$1,671
Clozapine11$473
Vilazodone Hcl12$454
Duloxetine Hcl39$397
Bupropion XlBupropion Hcl30$389
Venlafaxine Hcl ErVenlafaxine Hcl47$324
Mirtazapine32$280
Sertraline Hcl34$272
Buspirone Hcl48$262
Quetiapine Fumarate38$257

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$483$33,56123 claims
AbbVieVraylar$791$33,27521 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$14$8,14315 claims
Almatica Pharma LLCSertraline Hcl$24$27234 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 946 psychiatric/mental health providers in Kentucky.

Other psychiatric/mental health in Frankfort

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →